AbCellera Biologics (ABCL) Other Working Capital Changes (2020 - 2021)

AbCellera Biologics (ABCL) has 7 years of Other Working Capital Changes data on file, last reported at $1.7 million in Q1 2026.

• Quarterly Other Working Capital Changes fell 86.92% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$13.8 million (down 466.73% YoY) and the FY2025 annual result came in at -$2.2 million, up 63.13% from the prior year.
• Other Working Capital Changes rose to $1.9 million in Q1 2021, from $1.4 million in the prior quarter.
• In the past five years, Other Working Capital Changes ranged from a high of $1.9 million in Q1 2021 to a low of $1.4 million in Q1 2020.
• A 5-year average of -$1.4 million and a median of $149000.0 in 2022 frame the typical range for Other Working Capital Changes.
• Annual changes were most pronounced in 2023 — Other Working Capital Changes tumbled 9451.68% — and 2025, when it soared 735.47%.
• Tracing ABCL's Other Working Capital Changes over 5 years: stood at $149000.0 in 2022, then plunged by 9451.68% to -$13.9 million in 2023, then jumped by 64.5% to -$4.9 million in 2024, then rose by 8.79% to -$4.5 million in 2025, then jumped by 138.59% to $1.7 million in 2026.
• The last three Other Working Capital Changes figures came in at $1.7 million (Q1 2026), -$4.5 million (Q4 2025), and $15.8 million (Q3 2025), per Business Quant data.